Treatment of aggressive non-Hodgkin's lymphomas.
The aim of the study was to evaluate overall survival in patients with diagnosis DLBCL, comparing CHOP chemotherapy plus rituximab with CHOP alone, and standard plus intensive regimens (BEAM). Above mentioned regimens were compared in high risk patient, who were identified according to the CD10 expression with factors of IPI. 27 patients with diagnosis of diffuse large B-cell lymphomas were under observation. CD20 expression was assessed in all cases. Overall survival therapy was compared in three groups. I- primary refractory patients who undergone chemotherapy with CHOP regimen (9 patents); II - patients refractory to the standard added intensive chemotherapy regimens (BEAM) (10 patients). III - patients who were treated with combination CHOP plus rituximab (8 patients); As it shown on the figure overall survival was the highest in III group and composes 17 months, as for II and I groups overall survival was 7,4 and 8,8 months respectively. In summary based on our observations quantity of unfavorable prognostic factors may determine primary refractory patients to standard therapies and first line treatment in CD20 positive cases with CHOP plus Rituximab regimen increased overall survival from 7,4 month to 17 month (p<0,01).
Tsartsidze
E
E
Institute of Postgraduate Medical Education and Continuous Professional Development, Tbilisi State Medical University, Medulla-Chemotherapy and Immunotherapy Clinic Tbilisi, Georgia.
Betaneli
M
M
Sharikadze
N
N
Shavidze
N
N
Seskuria
N
N
D000293:Adolescent; D000328:Adult; D000368:Aged; D018450:Disease Progression; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D008875:Middle Aged; D011379:Prognosis